19 December 2025 With its landmark ruling, the court has delivered guidance for patentees and litigants— including three takeaways for counsel and rights holders, explain Tobias Wuttke and Axel Berger of Bardehle Pagenberg.
18 December 2025
17 December 2025
16 December 2025
15 December 2025
15 December 2025
Latest Features
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Latest Conference Videos
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
Unified Patent Court
Will James and Tim Harris, Osborne Clarke, discuss their experiences litigating life sciences cases before the UPC and share key insights from the court’s early decisions.
Americas
Brazil’s pharmaceutical IP landscape is shifting fast, and Juliana Neves of Licks unpacks how new reforms, guidelines, and rulings are resetting the strategic ground rules for innovators.
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN.
More News
11 December 2025 Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.
11 December 2025 The lateral hire from Covington & Burling will strengthen the firm's cross-border expertise as the UK and EU markets ‘navigate regulatory and technological shifts’, said the firm.
9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.
9 December 2025 New hires bring “exceptional technical expertise” and a strong track record across biotechnology and pharmaceutical patent matters.
9 December 2025 Solicitor General urges the US Supreme Court to hear an appeal in its dispute, arguing that a ruling threatens the future of skinny labelling and the availability of lower-cost generics.
8 December 2025 The firm has added a disputes specialist with experience in pharma, biotech and manufacturing sectors across multiple jurisdictions.
8 December 2025 As part of a broader bid to remove obstacles to patents, director Squires clarifies how examiners, applicants and practitioners may handle patent subject matter eligibility rejections.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox